Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin.
暂无分享,去创建一个
Wei Liang | H. Hang | W. Liang | Gangjun Du | Nan Wang | Gangjun Du | Haiying Hang | Ning Tang | Chunchun Liu | Nan Wang | N. Tang | Chunchun Liu
[1] A. Howell,et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Jessie L.-S. Au,et al. Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.
[3] R K Jain,et al. Barriers to drug delivery in solid tumors. , 1994, Scientific American.
[4] Vladimir P Torchilin,et al. Lipid-core micelles for targeted drug delivery. , 2005, Current drug delivery.
[5] Vladimir P. Torchilin,et al. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] Y. Sugiyama,et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. , 2003, Cancer research.
[7] G. Barratt,et al. Therapeutic applications of colloidal drug carriers. , 2000, Pharmaceutical science & technology today.
[8] R. Parton,et al. Regulated internalization of caveolae , 1994, The Journal of cell biology.
[9] K. Kataoka,et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel , 2005, British Journal of Cancer.
[10] Dai Fukumura,et al. Engineering vascularized tissue , 2005, Nature Biotechnology.
[11] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[12] Tae-You Kim,et al. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.
[13] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[14] C. Allen,et al. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[15] F M Muggia,et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Schacht,et al. Use of Block Copolymers of Poly(Ortho Esters) and Poly (Ethylene Glycol) Micellar Carriers as Potential Tumour Targeting Systems , 2003, Journal of drug targeting.
[17] T. Okano,et al. Development of the polymer micelle carrier system for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[18] V. Torchilin,et al. Diacyllipid-Polymer Micelles as Nanocarriers for Poorly Soluble Anticancer Drugs , 2002 .
[19] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[20] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[21] U. Huth,et al. Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[22] J. Lankelma,et al. Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[24] I. Tannock,et al. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. , 1989, Journal of the National Cancer Institute.
[25] Tao Xu,et al. Labeling and dynamic imaging of synaptic vesicle-like microvesicles in PC12 cells using TIRFM , 2004, Brain Research.
[26] R. Olson,et al. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] Angelo Corti,et al. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. , 2002, The Journal of clinical investigation.
[28] J. Lippincott-Schwartz,et al. Endocytosis without clathrin coats. , 2001, Trends in cell biology.
[29] H. Ueno,et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.
[30] M. Dewhirst,et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.
[31] P. Seglen,et al. Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin. , 1979, European journal of biochemistry.
[32] R. Jain,et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. , 2006, Blood.
[33] Lucas Pelkmans,et al. Endocytosis Via Caveolae , 2002, Traffic.
[34] Lothar Lilge,et al. The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.
[35] M. Weinand,et al. Human Immunodeficiency Virus Type 1 Enters Brain Microvascular Endothelia by Macropinocytosis Dependent on Lipid Rafts and the Mitogen-Activated Protein Kinase Signaling Pathway , 2002, Journal of Virology.